Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-beta-aminoisobutyric acid (L-BAIBA) is a naturally occurring non-protein amino acid and myokine produced by skeletal muscle during physical exercise through the catabolism of valine. Developed by Vedic Lifesciences for the treatment of obesity, L-BAIBA acts as a metabolic signaling molecule that promotes the browning of white adipose tissue into a thermogenic beige phenotype. Its biological mechanism involves the activation of the AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor delta (PPARδ) pathways, which collectively increase fatty acid oxidation in the liver and skeletal muscle while decreasing hepatic lipogenesis. Clinical studies have focused on evaluating the safety and metabolic efficacy of oral L-BAIBA supplementation in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-beta-aminoisobutyric acid.